What is the market buying in the Paras Healthcare IPO subscription? The Rs 1,450 crore issue closed on 23 October 2026 at 2.34 times, with listing expected on 28 October, and the answer lies in a hospital group with eight hospitals, 2,211 beds, a plan to reach 3,011 beds by March 2028 and a very recent turn to profit. The figures are as reported at about 5:00 PM IST on the final day and may change after reconciliation.
Key takeaways for the Paras Healthcare IPO subscription and the business
- Subscription closed at 2.34 times: qualified institutions 3.25 times, retail 2.10 times, non-institutional investors 0.69 times.
- The company reports revenue of Rs 1,605.95 crore in FY26, up from Rs 1,294.06 crore in FY25.
- It posted a FY26 profit of Rs 43.83 crore after a Rs 57.98 crore loss in FY25.
- About two-thirds of the issue is an offer for sale, by our calculation (Rs 950 crore of Rs 1,450 crore).
- Allotment is on 26 October and tentative listing on 28 October.
The hospital group behind the Paras Healthcare IPO subscription
As we reported in our earlier coverage, the company operates eight hospitals with 2,211 beds and targets 3,011 beds by March 2028, which would be an increase of 800 beds, or about 36%, by our calculation. For a hospital operator, beds are the basic unit of capacity, and growth usually depends on commissioning new facilities and raising occupancy at existing ones. The offer documents are filed with SEBI.
The company’s disclosures are the source for these numbers, and we have not independently audited them.
Financial turnaround in the Paras Healthcare IPO subscription story
Revenue rose from Rs 1,294.06 crore in FY25 to Rs 1,605.95 crore in FY26, an increase of about 24% by our calculation. The company moved from a loss of Rs 57.98 crore to a profit of Rs 43.83 crore over the same period. A swing of that size in one year can reflect higher occupancy, better pricing or one-off items; the sources we saw do not explain the drivers, so we do not attribute it.
How the Paras Healthcare IPO subscription unfolded
- Day one: 0.15 times.
- Day two: 0.36 times.
- Day three, 23 October: 2.34 times overall; QIB 3.25 times, retail 2.10 times, NII 0.69 times.
Bids totalled about 2,69,43,378 shares, around Rs 1,867 crore at the upper band according to one tally. The price band was Rs 660 to Rs 693, the lot 21 shares (Rs 14,553 at the top of the band) and face value Re 1. Anchor investors took 94,15,584 shares, or 45% of the net issue; names were not in the sources we read.
Questions investors ask after the Paras Healthcare IPO subscription
Several practical questions follow a closed issue. Will I get shares? That depends on the category and, in oversubscribed retail quotas, on a lottery; the retail allotment ratio has not been published in the sources we saw. When will refunds arrive? The schedule is 27 October for unsuccessful bids. Can I sell on the first day? Allotted shares credited to demat accounts can be sold from the listing day. What does a 2.34 times subscription imply for the price? Nothing reliable: demand at the issue price is not a forecast of trading levels.
Use of proceeds and the Paras Healthcare IPO subscription
Only the Rs 500 crore fresh issue (72,15,007 shares) raises money for the company. The Rs 950 crore offer for sale (1,37,08,513 shares) pays existing shareholders. For a company planning bed expansion, the size of the fresh component relative to its plans matters, and we have not set out the stated uses of proceeds here because we did not read the full offer document. JM Financial is the lead manager and MUFG Intime India the registrar, with allotment status at in.mpms.mufg.com.
Allotment and listing timeline
- 26 October: basis of allotment.
- 27 October: refunds and credit of shares.
- 28 October: tentative listing on BSE and NSE.
General background: how hospital IPOs are judged
Listed hospital companies in India are usually assessed on bed additions, occupancy, revenue per occupied bed and the pace at which new hospitals mature. Investors also look at debt, since hospitals are capital-intensive. The sources for this article do not provide occupancy or debt data, so we cannot apply those measures here.
Our analysis: growth story, thin earnings
In our assessment, the Paras Healthcare IPO subscription reflects a market willing to back a growth plan from a company that has only just reached profit. The post-issue market capitalisation of about Rs 7,498 crore at the upper band is roughly 170 times FY26 profit by our calculation, which implies investors are valuing future capacity more than current earnings.
The moderate retail and weak non-institutional demand suggest that not every group shares that view. We do not forecast the listing price and do not give investment advice.
What is not disclosed
- Occupancy, average revenue per bed and debt levels.
- Anchor investor names.
- Final reconciled subscription numbers.
- Stated uses of the fresh-issue proceeds.
Risks and caveats of the Paras Healthcare IPO subscription
Subscription figures are a snapshot and can be revised. Hospital businesses carry execution, regulatory and capital risks. We found no Acumen Research and Consulting report covering Indian hospital IPOs, so none is cited. This is news reporting and not investment advice.
What to watch next
- Allotment and refunds from 26 October.
- Listing and first-day trading on 28 October on nseindia.com and bseindia.com.
- The company’s first results as a listed entity.
- Progress on new beds toward the March 2028 target.
FAQ
What did the Paras Healthcare IPO subscription close at?
2.34 times overall on 23 October 2026.
How big is the issue?
Rs 1,450 crore, of which Rs 500 crore is fresh and Rs 950 crore an offer for sale.
Is the company profitable?
It reported a profit of Rs 43.83 crore in FY26 after a loss of Rs 57.98 crore in FY25.
How we reported this: we relied on exchange-linked subscription data and company issue details as reported, our own earlier coverage and the regulator and exchange sites linked above. Where figures are our calculations, we say so. Last updated 24 October 2026. This is news reporting and not advice.
